A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer

Exclusion Criteria

• •Have any type of active malignant tumor or have a history of malignant tumor.
• •Previously treated with Gemzar injection.
• •Known brain metastases, spinal cord compression, cancerous meningitis, or diseases of the brain or pia mater detected during Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) screening.
• •Clinically significant ascites in patients.
• •Diarrhea greater than or equal to level 2.
• •Have any acute or chronic active infectious disease.
• •Hypertensive patients who cannot be well controlled, or suffering from myocardial ischemia or myocardial infarction, arrhythmia, and grade I heart failure.
• •Urine routine indicates urine protein ≥++, and it is confirmed that the 24-hour urine protein quantification is greater than 1.0 g.
• •History of abdominal fistula, gastrointestinal perforation, or abdominal abscess within 6 months.
• •Long term unhealed wounds or fractures.
• •Individuals who have experienced arterial/venous thrombosis events within 6 months, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis, and pulmonary embolism.
• •Patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin, or their analogues; Under the premise that international normalized ratio (INR) is ≤ 1.5, it is allowed to use low-dose warfarin (1mg orally, once daily) or low-dose aspirin (not exceeding 100mg daily) for preventive purposes.
• •Individuals with a history of psychiatric drug abuse who are unable to quit or have mental disorders.
• •Patients known to be allergic to Gemzar injection.
• •Patients with active hepatitis B or hepatitis C.
• •Individuals with a history of immunodeficiency, including HIV testing positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.
• •According to the investigator's judgment, there are accompanying diseases that seriously endanger patient safety or affect the completion of the study.